Perception of symptoms in hypertensive patients and the relevance to application of anti-hypertensive drug therapy

Current Pharmaceutical Design

Volumn 12, Issue 13, 2006, Pages 1557-1565

  Goyal, Deepak ^a   MacFadyen, Robert J ^a  

^a CITY HOSPITAL   (United Kingdom)

Author keywords

Hypertension; Quality of life; Symptom perception

Indexed keywords

ACEBUTOLOL; AMLODIPINE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXAZOSIN; ENALAPRIL; EPLERENONE; HYDROCHLOROTHIAZIDE; NIFEDIPINE; NITRENDIPINE; PLACEBO; PROPRANOLOL; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT;

ANGIONEUROTIC EDEMA; ANKLE EDEMA; ANOREXIA; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; BRONCHOSPASM; CLAUDICATION; CLINICAL FEATURE; CLINICAL TRIAL; CONSTIPATION; COUGHING; DATA BASE; DIABETES MELLITUS; DIARRHEA; DISEASE EXACERBATION; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG ERUPTION; DRY EYE; DYSPEPSIA; DYSPNEA; ESSENTIAL HYPERTENSION; EXERCISE TOLERANCE; FATIGUE; FLUSHING; FREQUENCY ANALYSIS; GOUT; GYNECOMASTIA; HEADACHE; HUMAN; HYPERKALEMIA; HYPERTENSION; IMPOTENCE; INFORMATION PROCESSING; INSOMNIA; LETHARGY; NAUSEA; ORTHOSTATIC HYPOTENSION; OUTCOME ASSESSMENT; PARESTHESIA; PATIENT CARE; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; PSORIASIS; QUALITY OF LIFE; REVIEW; SEXUAL DYSFUNCTION; SLEEP DISORDER; SYSTEMIC LUPUS ERYTHEMATOSUS; TASTE DISORDER; TINNITUS; XEROSTOMIA;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; DIURETICS; HUMANS; HYPERTENSION; PATIENT COMPLIANCE; PERCEPTION; QUALITY OF LIFE;

EID: 33646506179     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161206776843377     Document Type: Review

References (74)

1. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet 2005; 365(9455): 217-223.
2. Neal B, MacMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet 2000; 356(9246): 1955-1964.
3. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42(6): 1206-1252.
4. Kaplan NM. Anxiety-induced hyperventilation. A common cause of symptoms in patients with hypertension. Arch Intern Med 1997; 157(9): 945-948.
5. Kullman S, Svardsudd K. Differences in perceived symptoms/quality of life in untreated hypertensive and normotensive men. Scand J Prim Health Care Suppl 1990; 1: 47-53.
6. Kannel WB. Potency of vascular risk factors as the basis for antihypertensive therapy. Eur Heart J 1992; 13(Suppl G): 34-42.
7. Natarajan S, Nietert PJ. Hypertension, diabetes, hypercholesterolemia and their combinations increased health care utilization and decreased health status. J Clin Epidemiol 2004; 57: 954-961.
8. Haynes RB, Sackett DL, Taylor DW, Gibson ES, Johnson AL. Increased absenteeism from work after detection and labeling of hypertensive patients. N Engl J Med 1978; 299(14): 741-744.
9. Beckman HB, Frankel RM The effect of physician behavior on the collection of data. Ann Int Med 1984; 101: 692-696.
10. Suarez-Almazor ME, Conner-Spady B, Kendall CJ, Russell AS, Skeith K. Lack of congruence in the ratings of patients health status by patients and their physicians. Med Decis Making 2001; 21: 113-121.
11. Orth JE, Stiles WB, Scherwitz L, Hennrikus D, Vallbona C. Patient exposition and provider explanation in routine interviews and hypertensive patients blood pressure control. Health Psychol 1987; 6: 29-42.
12. Jachuck SJ, Brierley H, Jachuck S, Willcox PM. The effect of hypotensive drugs on the quality of life. J R Coll Gen Pract 1982; 32(235): 103-105.
13. Kilander L, Nyman H, Boberg M, Hansson L, Lithell H. Hypertension is related to cognitive impairment: a 20-year follow-up of 999 men. Hypertension 1998; 31(3): 780-786.
14. Starr JM, Whalley LJ. Senile hypertension and cognitive impairment: an overview. J Hypertens Suppl 1992; 10(2): S31-S42
15. Patrick DL, Bergner M. Measurement of health status in the 1990s. Annu Rev Public Health 1990; 11: 165-183.
16. Calman KC. Quality of life in cancer patients - an hypothesis. J Med Ethics 1984; 10(3): 124-127.
17. James MA, Potter JF. The effect of antihypertensive treatment on the quality of later years. Drugs Aging 1993; 3(1): 26-39.
18. Sanders C, Egger M, Donovan J, Tallon D, Frankel S. Reporting on quality of life in randomised controlled trials: bibliographic study. BMJ 1998; 317(7167): 1191-1194.
19. Gill TM, Feinstein AR. A critical appraisal of the quality of quality-of-life measurements. JAMA 1994; 272(8): 619-626.
20. Fitzpatrick R, Fletcher A, Gore S, Jones D, Spiegelhalter D, Cox D. Quality of life measures in health care. I: Applications and issues in assessment. BMJ 1992; 305(6861): 1074-1077.
21. Coyne KS, Davis D, Frech F, Hill MN. Health-related quality of life in patients treated for hypertension: a review of the literature from 1990 to 2000. Clin Ther 2002; 24(1): 142-169.
22. Engelmann MD, Pehrson S. Quality of life in non-pharmacologic treatment of atrial fibrillation. Eur Heart J 2003; 24(15): 1387-1400.
23. Enlund H, Jokisalo E, Wallenius S, Korhonen M. Patient-perceived problems, compliance, and the outcome of hypertension treatment. Pharm World Sci 2001; 23(2): 60-64.
24. Rudd P. Clinicians and patients with hypertension: unsettled issues about compliance. Am Heart J 1995; 130(3 Pt 1): 572-579.
25. Eraker SA, Kirscht JP, Becker MH. Understanding and improving patient compliance. Ann Intern Med 1984; 100(2): 258-268.
26. Erdine S. How well is hypertension controlled in Europe? J Hypertens 2000; 18(9): 1348-1349.
27. Jones JK, Gorkin L, Lian JF, Staffa JA, Fletcher AP. Discontinuation of and changes in treatment after start of new courses of antihypertensive drugs: a study of a United Kingdom population. BMJ 1995; 311(7000): 293-295.
28. Rizzo JA, Simons WR. Variations in compliance among hypertensive patients by drug class: implications for health care costs. Clin Ther 1997; 19(6): 1446-1457.
29. Caro JJ, Salas M, Speckman JL, Raggio G, Jackson JD. Persistence with treatment for hypertension in actual practice. CMAJ 1999; 160(1): 31-37.
30. Caro JJ, Speckman JL, Salas M, Raggio G, Jackson JD. Effect of initial drug choice on persistence with antihypertensive therapy: the importance of actual practice data. CMAJ 1999; 160(1): 41-46.
31. Thrall G, Lip GY, Lane D. Compliance with pharmacological therapy in hypertension: can we do better, and how? J Hum Hypertens 2004; 18(9): 595-597.
32. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288(23): 2981-2997.
33. Applegate WB. Quality of life during antihypertensive treatment. Lessons from the Systolic Hypertension in the Elderly Program. Am J Hypertens 1998; 11(3 Pt 2): 57S-61S.
34. Fletcher A. Quality of life in the management of hypertension. Clin Exp Hypertens 1999; 21(5-6): 961-972.
35. Wassertheil-Smoller S, Blaufox MD, Oberman A, Davis BR, Swencionis C, Knerr MO, et al. Effect of antihypertensives on sexual function and quality of life: the TAIM Study. Ann. Intern. Med 1991; 114(8): 613-620.
36. Grimm RH, Jr., Grandits GA, Prineas RJ, McDonald RH, Lewis CE, Flack JM, et al. Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women. Treatment of Mild Hypertension Study (TOMHS). Hypertension 1997; 29(1 Pt 1): 8-14.
37. White WB, Carr AA, Krause S, Jordan R, Roniker B, Oigman W. Assessment of novel selective aldosterone blocker eplerenone using ambulatory and clinical blood pressure in patients with systemic hypertension. Am J Cardiol 2003; 92: 38-42.
38. Hollenberg NK, Williams GH, Anderson R, Akhras KS, Bittman RM, Krause SL. Symptoms and the distress they cause: comparison of an aldosterone antagonist and a calcium channel blocking agent in patients with systolic hypertension. Arch Intern Med 2003; 163(13): 1543-1548.
39. Solomon S, Hotchkiss E, Saravay SM, Bayer C, Ramsey P, Blum RS. Impairment of memory function by antihypertensive medication. Arch Gen Psychiatry 1983; 40(10): 1109-1112.
40. McAinsh J, Cruickshank JM. Beta-blockers and central nervous system side effects. Pharmacol Ther 1990; 46(2): 163-197.
41. Thiessen BQ, Wallace SM, Blackburn JL, Wilson TW, Bergman U. Increased prescribing of antidepressants subsequent to beta-blocker therapy. Arch Intern Med 1990; 150(11): 2286-2290.
42. Palac DM, Cornish RD, McDonald WJ, Middaugh DA, Howieson D, Bagby SP. Cognitive function in hypertensives treated with atenolol or propranolol. J Gen Intern Med 1990; 5(4): 310-318.
43. Perez-Stable EJ, Halliday R, Gardiner PS, Baron RB, Hauck WW, Acree M, et al. The effects of propranolol on cognitive function and quality of life: a randomized trial among patients with diastolic hypertension. Am J Med 2000; 108(5): 359-365.
44. Fogari R, Zoppi A, Corradi L, Mugellini A, Poletti L, Lusardi P. Sexual function in hypertensive males treated with lisinopril or atenolol: a cross-over study. Am J Hypertens 1998; 11(10): 1244-1247.
45. Fogari R, Zoppi A, Poletti L, Marasi G, Mugellini A, Corradi L. Sexual activity in hypertensive men treated with valsartan or carvedilol: a crossover study. Am J Hypertens 2001; 14(1): 27-31.
46. Fogari R, Preti P, Derosa G, Marasi G, Zoppi A, Rinaldi A, et al. Effect of antihypertensive treatment with valsartan or atenolol on sexual activity and plasma testosterone in hypertensive men. Eur J Clin Pharmacol 2002; 58(3): 177-180.
47. Suzuki H, Tominaga T, Kumagai H, Saruta T. Effects of first-line antihypertensive agents on sexual function and sex hormones. J Hypertens Suppl 1988; 6(4): S649-S651.
48. Grimm RH, Jr., Grandits GA, Prineas RJ, McDonald RH, Lewis CE, Flack JM, et al. Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women. Treatment of Mild Hypertension Study (TOMHS). Hypertension 1997; 29(1 Pt 1): 8-14.
49. Palmer A, Fletcher A, Hamilton G, Muriss S, Bulpitt C. A comparison of verapamil and nifedipine on quality of life. Br J Clin Pharmacol 1990; 30(3): 365-370.
50. Fletcher AE, Battersby C, Adnitt P, Underwood N, Jurgensen HJ, Bulpitt CJ. Quality of life on antihypertensive therapy: a double-blind trial comparing quality of life on pinacidil and nifedipine in combination with a thiazide diuretic. European Pinacidil Study Group. J Cardiovasc Pharmacol 1992; 20(1): 108-114.
51. Maxwell CJ, Hogan DB, Ebly EM. Calcium-channel blockers and cognitive function in elderly people: results from the Canadian Study of Health and Aging. CMAJ 1999; 161(5): 501-506.
52. Forette F, Seux ML, Staessen JA, Thijs L, Birkenhager WH, Babarskiene MR, et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet 1998; 352(9137): 1347-1351.
53. Fletcher AE, Bulpitt CJ, Thijs L, Tuomilehto J, Antikainen R, Bossini A, et al. Quality of life on randomized treatment for isolated systolic hypertension: results from the Syst-Eur Trial. J Hypertens 2002; 20(10): 2069-2079.
54. Testa MA, Turner RR, Simonson DC, Krafcik MB, Calvo C, Luque-Otero M. Quality of life and calcium channel blockade with nifedipine GITS versus amlodipine in hypertensive patients in Spain. J Hypertens 1998; 16(12 Pt 1): 1839-1847.
55. Leonetti G, Magnani B, Pessina AC, Rappelli A, Trimarco B, Zanchetti A. Tolerability of long-term treatment with lercanidipine versus amlodipine and lacidipine in elderly hypertensives. Am J Hypertens 2002; 15(11): 932-940.
56. Croog SH, Levine S, Testa MA, Brown B, Bulpitt CJ, Jenkins CD, et al. The effects of antihypertensive therapy on the quality of life. N Engl J Med 1986; 314(26): 1657-1664.
57. Fletcher AE, Bulpitt CJ, Hawkins CM, Havinga TK, ten Berge BS, May JF, et al. Quality of life on antihypertensive therapy: a randomized double-blind controlled trial of captopril and atenolol. J Hypertens 1990; 8(5): 463-466.
58. Palmer AJ, Fletcher AE, Rudge PJ, Andrews CD, Callaghan TS, Bulpitt CJ. Quality of life in hypertensives treated with atenolol or captopril: a double-blind crossover trial. J Hypertens 1992; 10(11): 1409-1416.
59. Steiner SS, Friedhoff AJ, Wilson BL, Wecker JR, Santo JP. Anti-hypertensive therapy and quality of life: a comparison of atenolol, captopril, enalapril and propranolol. J Hum Hypertens 1990; 4(3): 217-225.
60. Gard PR. The role of angiotensin II in cognition and behaviour. Eur J Pharmacol 2002; 438(1-2): 1-14.
61. Dietrich B, Herrmann WM. Influence of cilazapril on memory functions and sleep behaviour in comparison with metoprolol and placebo in healthy subjects. Br J Clin Pharmacol 1989; 27(Suppl 2): 249S-261S.
62. Starr JM, Whalley LJ, Deary IJ. The effects of antihypertensive treatment on cognitive function: results from the HOPE study. J Am Geriatr Soc 1996; 44(4): 411-415.
63. PROGRESS. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358(9287): 1033-1041.
64. Fogari R, Zoppi A. Effects of antihypertensive therapy on sexual activity in hypertensive men. Curr Hypertens Rep 2002; 4(3): 202-210.
65. Raghavendra V, Chopra K, Kulkarni SK. Comparative studies on the memory-enhancing actions of captopril and losartan in mice using inhibitory shock avoidance paradigm. Neuropeptides 2001; 35(1): 65-69.
66. Tedesco MA, Ratti G, Mennella S, Manzo G, Grieco M, Rainone AC, et al. Comparison of losartan and hydrochlorothiazide on cognitive function and quality of life in hypertensive patients. Am J Hypertens 1999; 12(11 Pt 1): 1130-1134.
67. Fogari R, Mugellini A, Zoppi A, Marasi G, Pasotti C, Poletti L, et al. Effects of valsartan compared with enalapril on blood pressure and cognitive function in elderly patients with essential hypertension. Eur J Clin Pharmacol 2004; 59(12): 863-868.
68. Hansson L, Lithell H, Skoog I, Baro F, Banki CM, Breteler M, et al. Study on COgnition and Prognosis in the Elderly (SCOPE). Blood Press 1999; 8(3): 177-183.
69. Betancourt JR, Carrillo JE, Green AR. Hypertension in multicultural and minority populations: linking communication to compliance. Curr Hypertens Rep 1999; 1(6): 482-488.
70. Phillips LS, Branch WT, Cook CB, Doyle JP, El Kebbi IM, Gallina DL, et al. Clinical inertia. Ann Intern Med 2001; 135(9): 825-834.
71. Hill MN, Miller NH. Compliance enhancement. A call for multidisciplinary team approaches. Circulation 1996; 93(1): 4-6.
72. Coppage KH, Sibai BM. Treatment of hypertensive complications in pregnancy. Curr Pharm Des 2005; 11(6): 749-57.
73. Grandi AM. Antihypertensive therapy: role of aldosterone antagonists. Curr Pharm Des 2005; 11(17): 2235-42.
74. Sosin MD, Bhatia GS, Lip GY, Davis RC. Drug development and the importance of ethnicity: lessons from heart failure management and implications for hypertension. Curr Pharm Des 2004; 10(29): 3569-77.